HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A review of tasquinimod in the treatment of advanced prostate cancer.

Abstract
Castration resistant prostate cancer remains a major clinical burden and novel therapeutic options are urgently required to improve survival. Tasquinimod is an orally administered quinoline-3-carboxamide with potent antiangiogenic and antitumorigenic action that has shown promise in the treatment of advanced prostate cancers. This review explores both preclinical and clinical findings to date. In summary, tasquinimod has been shown to demonstrate a potent in vitro and in vivo anticancer action and completed early phase clinical trials have demonstrated good drug tolerance and prolonged progression-free survival. Although Phase III clinical trials are on-going, the findings to date highlight the promise of this drug in the treatment of advanced prostate cancer.
AuthorsStuart Charles Williamson, Alice Elizabeth Hartley, Rakesh Heer
JournalDrug design, development and therapy (Drug Des Devel Ther) Vol. 7 Pg. 167-74 ( 2013) ISSN: 1177-8881 [Electronic] New Zealand
PMID23662046 (Publication Type: Journal Article, Review)
Chemical References
  • Angiogenesis Inhibitors
  • Quinolines
  • Quinolones
  • tasquinimod
Topics
  • Angiogenesis Inhibitors (therapeutic use)
  • Animals
  • Clinical Trials as Topic
  • Drug Discovery
  • Drug Screening Assays, Antitumor
  • Humans
  • Male
  • Prostatic Neoplasms (drug therapy)
  • Quinolines (pharmacology, therapeutic use)
  • Quinolones

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: